Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02161224
Recruitment Status : Completed
First Posted : June 11, 2014
Last Update Posted : June 11, 2014
Sponsor:
Collaborator:
FibroGen
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )

Brief Summary:
The effect of moderately diminished liver function on the exposure, safety and tolerability of a single dose of FG-4592 is studied in male and female subjects. The results are compared to the data gained from subjects with normal liver function.

Condition or disease Intervention/treatment Phase
PK of FG-4592 Hepatic Insufficiency Healthy Subjects Drug: FG-4592 Phase 1

Detailed Description:

The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety and tolerability of a single dose of FG-4592 in male and female subjects is investigated. Data obtained from these subjects are compared to data from BMI-, age- and sex-matched subjects with normal hepatic function. Both groups consist of 8 subjects.

Screening takes place from Days -22 to -2 before admission to the clinical unit on Day -1. Administration of the trial medication takes place on Day 1 under fasted conditions. Healthy subjects are discharged on Day 5 and subjects with moderate hepatic impairment on Day 7, if there is no reason to extend the stay. An end-of-study visit (ESV) takes place 5 to 9 days after (early) discharge.

Safety assessments are performed throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of FG-4592 in Subjects With Moderate Hepatic Impairment and Healthy Subjects With Normal Hepatic Function
Study Start Date : September 2013
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: 1: FG-4592 in subjects with moderate hepatic impairment Drug: FG-4592
Oral
Other Names:
  • ASP1517,
  • roxadustat

Experimental: 2: FG-4592 in healthy subjects Drug: FG-4592
Oral
Other Names:
  • ASP1517,
  • roxadustat




Primary Outcome Measures :
  1. Pharmacokinetic parameter of FG-4592 in plasma as measured by area under the concentration-time curve (AUC) extrapolated to infinity (AUCinf) [ Time Frame: Days 1 to 5 (Day 7 for hepatic impaired subjects) ]
  2. Pharmacokinetic parameter of FG-4592 in plasma as measured by maximum concentration (Cmax) [ Time Frame: Days 1 to 5 (Day 7 for hepatic impaired subjects) ]

Secondary Outcome Measures :
  1. Pharmacokinetic profile of FG-4592 in plasma [ Time Frame: Days 1 to 5 (Day 7 for hepatic impaired subjects) ]
    AUC up to last quantifiable concentration (AUClast), AUC from 0 up to last quantifiable concentration based on unbound plasma concentration (AUClast,u), AUC from time point 0 to time point 24 hours (AUC0-24h), AUC from time point 0 to time point 24 hours based on unbound plasma concentration (AUC0-24h,u), unbound AUC extrapolated to infinity (AUCinf,u), unbound maximum concentration (observed) (Cmax,u), apparent total systemic clearance after extra-vascular dosing (CL/F), plasma clearance over bioavailability ratio based on unbound plasma (CLu/F), fraction unbound (fu), lag-time (time delay between drug administration and first observed concentration above the Limit of Quantification (LOQ) in plasma) (tlag), time to attain Cmax (tmax), apparent terminal elimination half-life (t1/2), apparent volume of distribution during terminal phase after oral administration (Vz/F), unbound apparent volume of distribution during terminal phase after oral administration (Vz,u/F)

  2. Pharmacokinetic profile of FG-4592 in urine [ Time Frame: Days 1 to 5 (Day 7 for hepatic impaired subjects) ]
    renal clearance (CLR), renal clearance based on unbound concentration (CLR,u), renal clearance from time point 0 to 24 hours (CLR,0-24h), renal clearance from time point 0 to 24 hours based on unbound concentration (CLR,u 0-24h), amount of unchanged drug excreted into urine from time point 0 to infinity (Aeinf), amount of unchanged drug excreted into urine from time point 0 to infinity, percentage of dose (Aeinf%), amount of unchanged drug excreted into urine until the last observation time point (Aelast), amount of unchanged drug excreted into urine until the last observation time, percentage of dose (Aelast%), amount of drug excreted into urine from time point 0 to time point 24 hours (Ae0-24h), amount of drug excreted into urine from time point 0 to time point 24 hours, percentage of dose (Ae0-24h%)

  3. Erythropoietin in plasma [ Time Frame: Days 1 to 5 (Day 7 for hepatic impaired subjects) ]
    maximum achievable pharmacologic effect (Emax), area under the concentration-time curve from 0 up to last quantifiable concentration based on EPO concentration (AUCE,last), tmax

  4. Safety and tolerability of FG-4592 [ Time Frame: Screening (Days -22 to -2) to ESV (5 to 9 days after (early) discharge) ]
    Nature, frequency and severity of adverse events (AEs), vital signs, safety laboratory tests, electrocardiogram



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Both healthy subjects and subjects with moderate hepatic impairment:

  • Independent Ethics Committee (IEC)-approved written Informed Consent and privacy language as per national regulations must be obtained from the subject prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
  • Male subjects and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continuing throughout the study period and for 90 days after the study drug administration.

In addition, subjects with moderate hepatic impairment must also meet the following inclusion criteria:

  • Subject has Child-Pugh classification Class B (moderate, 7 to 9 points) liver function impairment [screening].

Exclusion Criteria:

Both healthy subjects and subjects with moderate hepatic impairment:

  • Female subject who has been pregnant within 6 months prior to screening or breastfeeding within 3 months before screening.
  • Subject has a known or suspected hypersensitivity to FG-4592, or any components of the formulation used.

In addition, healthy subjects must also NOT meet the following exclusion criteria:

  • Subject has any of the liver function tests (LFT) (Aspartate Aminotransferase [AST], Alanine Aminotransferase [ALT], Alkaline Phosphatase [ALP], Gamma Glutamyl Transferase [GGT], Total Bilirubin [TBL] above the upper limit of normal (ULN). In such a case the assessment may be repeated once [Day-1].

In addition, subjects with moderate hepatic impairment must also NOT meet the following exclusion criteria:

  • Subject had a previous liver transplantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02161224


Locations
Layout table for location information
Bulgaria
COMAC
Sofia, Bulgaria
Sponsors and Collaborators
Astellas Pharma Europe B.V.
FibroGen
Investigators
Layout table for investigator information
Study Director: Central contact Astellas Pharma Europe B.V.
Layout table for additonal information
Responsible Party: Astellas Pharma Europe B.V.
ClinicalTrials.gov Identifier: NCT02161224    
Other Study ID Numbers: 1517-CL-0513
2013-001533-41 ( EudraCT Number )
First Posted: June 11, 2014    Key Record Dates
Last Update Posted: June 11, 2014
Last Verified: June 2014
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe B.V. ):
Phase 1
FG-4592
Single dose
Moderate hepatic impairment
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatic Insufficiency
Liver Failure
Liver Diseases
Digestive System Diseases